Inhibiting RIPK3 activity has been extensively explored by many researchers as a direction for suppressing necroptosis and proved effective; furthermore, boosting RIPK3 O-GlcNAcylation can diminish RIPK3 activation, thereby inhibiting necroptosis and ultimately relieving colitis [165]. This evidence concerns the gene RIPK3 and colitis.